NEWTON-CABG: Evolocumab Did Not Improve Vein Graft Patency After CABG
Key Points: Saphenous vein graft (SVG) failure is common after coronary artery…
In-Hospital Dapagliflozin Does Not Reduce CV Death or Worsening HF in Two Months, but Meta-Analysis Signals Potential Early Benefit
Key Points: Dapagliflozin is a key component of GDMT for heart failure,…
AI-Powered Virtual Assistant Boosts GDMT Optimization. ASSIST-HF SIRIO
Key Points: Optimization of GDMT is critical, particularly in the initial months…
Sacubitril/Valsartan Outperforms Enalapril in HFrEF due to Chronic Chagas Cardiomyopathy (CCC): The PARACHUTE-HF Trial
Key Points: Chronic Chagas cardiomyopathy (CCC) patients are underrepresented in heart failure…
An AI-enabled Stethoscope for Early Detection of Cardiac Conditions Increases Detection: TRICORDER
Key Points: Eighty percent of HF cases are diagnosed only during emergency…
Home-Based Hypertension Care Significantly Lowers Blood Pressure in Rural South Africa: The IMPACT-BP Trial
Key Points: Hypertension (HTN) is a major driver of stroke and cardiovascular…
Zilebesiran May Benefit Selected Groups of Uncontrolled Hypertension with High CV Risk: KARDIA-3
Key Points: Many patients do not achieve BP goals in hypertension (HTN)…
Essence-TIMI 73b: Olezarsen Safely and Effectively Reduces Triglycerides in Patients With Moderate Hypertriglyceridemia and High CV Risk
Key Points: Olezarsen, an anti-sense oligonucleotide targeting APOC3 mRNA, is approved to…
VICTOR: Vericiguat Did Not Meet Primary Endpoint But Reduced CV Death in Stable, Ambulatory HFrEF
Key Points: The VICOTRIA trial previously demonstrated that vericiguat reduced the risk…
VICTOR + VICTORIA: Vericiguat Showed Benefits Across the Spectrum of HFrEF Severity
Key Points: VICTORIA and VICTOR and were randomized trials that evaluated vericiguat…
ABC-AF Trial: Personalized Risk-Based Treatment Did Not Improve Outcomes in Patients with Atrial Fibrillation
Key Points: The ABC-AF trial evaluated whether treatment recommendations based on biomarker-based…
BaxHTN: Baxdrostat Significantly Reduced Blood Pressure in Patients with Uncontrolled or Resistant Hypertension
Key Points: Uncontrolled and resistant hypertension remains a major challenge despite treatment…
HI-PRO Trial: Extended Low-Intensity Apixaban Reduces Recurrent VTE in Patients with Provoked VTE and Enduring Risk Factors
Key Points: Standard anticoagulation for provoked venous thromboembolism (VTE) is often discontinued…
MAPLE-HCM: Aficamten Superior to Metoprolol for Improving Exercise Capacity in Symptomatic Obstructive HCM
Key Points: Beta-blockers are widely used as first-line therapy for obstructive hypertrophic…
An Invasive vs Conservative Strategy Safe But Does Improve MACE in Frail Older NSTEMI Patients: SENIOR-RITA Frail
Key Points: Evidence for NSTEMI management among older adults is limited, and…
LOSE-AF: Weight Loss Alone Does Not Improve AF Symptoms or Burden in Older Adults
Key Points: LOSE-AF is the first randomized trial to rigorously assess the…
ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction
KEY POINTS: In this prespecified exploratory analysis of the AEGIS-II trial, the…
Apolipoprotein A-I infusions Lowers Risk of Recurrent CV Events in Patients With Baseline LDL-C ≥100 mg/dL
KEY POINTS: In this exploratory analysis of the AEGIS-II randomized control trial,…
Improved Accuracy of HF Diagnosis with HFDetect-AI
Key Points: HFDetect-AI significantly improves the accuracy of diagnosing heart failure by…
Pre-Hospital Pulse-Dose Glucocorticoid Did not Reduce Infarct Size in STEMI: PULSE-MI
Key Points: The PULSE-MI trial assessed the effects of pre-hospital pulse-dose glucocorticoid…